Serum β 2-microglobulin in myelomatosis: potential value in stratification and monitoring | Zendy

D. R. Norfolk | Zendy; J. A. Child | Zendy; E.H. Cooper | Zendy; S.M. Kerruish | Zendy; Alexandra M. Ward | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum β 2-microglobulin in myelomatosis: potential value in stratification and monitoring

Author(s) -

D. R. Norfolk,

J. A. Child,

E.H. Cooper,

S.M. Kerruish,

Alexandra M. Ward

Publication year - 1980

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1980.273

Subject(s) - beta 2 microglobulin , creatinine , medicine , beta (programming language) , multiple myeloma , risk stratification , gastroenterology , beta globulins , stratification (seeds) , immunology , biology , antibody , gamma globulin , computer science , programming language , seed dormancy , botany , germination , dormancy

In a longitudinal study of the evolution of serum beta 2-microglobulin (beta 2-m) levels in 37 patients with myelomatosis, those patients with a level of < 4 mg/l at first presentation had a median survival of 46 months, whereas those with an initial level of > mg/l had a median survival of 15 months. THe beta 2-m appeared to be independent of the level of the paraprotein and its class, as seen in a vertical study of 129 patients. Analysis of the influence of a rising serum creatinine on the serum beta 2-m indicates that beta 2-m production is excessive in advanced disease with or without renal failure. Practical application of the measurement of serum beta 2-m in the stratification and monitoring of patients is suggested.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research